[{"from": "human", "value": "Provide a description of this molecule. [C][C@@H1][C][=Branch1][C][=O][N][C@H1][Branch2][Branch2][S][C][=Branch1][C][=O][N][C@@H1][Branch2][#Branch1][=C][C][=Branch1][C][=O][N][C@H1][Branch2][=Branch1][N][C][=Branch1][C][=O][N][C@H1][Branch2][Branch1][Branch1][C][=Branch1][C][=O][N][C@@H1][Branch2][Ring2][#Branch1][C][S][S][C][C@@H1][Branch1][=Branch2][C][=Branch1][C][=O][N][Ring2][Ring1][=N][N][C][=Branch1][C][=O][C@H1][Branch1][#Branch2][C][C][C][N][=C][Branch1][C][N][N][N][C][=Branch1][C][=O][C][C][=Branch1][C][=O][N][C][C][=C][N][C][=C][C][=C][C][=C][Ring1][=Branch1][Ring1][=Branch2][C][C][C][N][=C][Branch1][C][N][N][C][C][=C][C][=C][C][=C][Ring1][=Branch1][C][C][=C][N][=C][N][Ring1][Branch1]"}, {"from": "gpt", "value": "The molecule is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies. It is an agonist of the melanocortin 4 receptor. Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. Other earlier treatments for these patients included gastric bypass surgery. Patients taking setmelanotide experienced an average weight loss of 0.6 kg/week.  Imcivree was granted EMA orphan designation on 19 November 2018 and FDA approval on 25 November 2020."}]